Macrophages give Gas(6) to cancer

Blood

Volumn 115, Issue 11, 2010, Pages 2122-2123

  Sica, Antonio ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; GROWTH ARREST SPECIFIC PROTEIN 6; HYPOXIA INDUCIBLE FACTOR 1; INTERLEUKIN 10; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ANGIOGENESIS; APOPTOSIS; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVATION; HUMAN; INFLAMMATION; KIDNEY CARCINOMA; METASTASIS; MICROENVIRONMENT; NATURAL KILLER CELL; NOTE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN INTERACTION; THROMBOCYTE AGGREGATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH;

EID: 77950442118     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-12-255869     Document Type: Note

References (13)

1. Loges S, Schmidt T, Tjwa M, et al. Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6. Blood. 2010;115(11):2264-2273.
2. Manfioletti G, Brancolini C, Avanzi G, Schneider C. The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. Mol Cell Biol. 1993;13(8):4976-4985. (Pubitemid 23220402)
3. Linger RM, Keating AK, Earp HS, Graham DK.TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res. 2008;100:35-83.
4. Goruppi S, Ruaro E, Schneider C. Gas6, the ligand of Axl tyrosine kinase receptor, has mitogenic and survival activities for serum starved NIH3T3 fibroblasts. Oncogene. 1996;12(3):471-480. (Pubitemid 26059640)
5. Angelillo-Scherrer A, de Frutos P, Aparicio C, et al. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med. 2001;7(2):215-221. (Pubitemid 32148489)
6. Gustafsson A, Boström AK, Ljungberg B, Axelson H, Dahlbäck B. Gas6 and the receptor tyrosine kinase Axl in clear cell renal cell carcinoma. PLoS ONE. 2009;4(10):e7575.
7. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436-444.
8. Biswas SK, Gangi L, Paul S, et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood. 2006;107(5):2112-2122. (Pubitemid 43289397)
9. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 2007;117(5):1155-1166. (Pubitemid 46718400)
10. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol. 2009;27:693-733.
11. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3(10):721-732.
12. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66(2):605-612.
13. Phillips RJ, Mestas J, Gharaee-Kermani M, et al. Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/ mammalian target of rapamycin signalingz pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem. 2005;280(23):22473-22481. (Pubitemid 40827903)